Cholesterol Particle Size Testing: The Complete FM Practitioner Guide

The standard lipid panel is the most commonly ordered lab in medicine — and one of the most incomplete risk assessments you can run on a metabolically complex patient. This guide covers everything functional medicine practitioners need to know about cholesterol particle size testing: LDL Pattern A vs B, NMR Lipoprofile interpretation, LDL-P risk thresholds, and the treatment protocols that actually move the needle.

Bookmark this page. If you order advanced lipid testing in your practice, you'll come back to it.

The number printed as "LDL cholesterol" on a standard lipid panel measures the amount of cholesterol packed inside LDL particles. It tells you nothing about how many particles are circulating, how small and dense they are, or how readily they penetrate the arterial wall.

That distinction — particle mass vs. particle count vs. particle morphology — is the clinical gap that cholesterol particle size testing is built to fill. The Framingham Offspring Study showed LDL particle number (LDL-P) outperformed LDL-C in predicting cardiovascular events over a 15-year follow-up. MESA trial data confirmed that when LDL-P and LDL-C are discordant, events track with LDL-P. The case for going beyond the standard panel is well-established. The challenge is knowing exactly what to order, how to interpret it, and what to do when the results show elevated risk.

This guide answers all of that.

→ Lab Interpretation Hub

---

Table of Contents

1. Why Particle Size Matters More Than LDL-C
2. LDL Pattern A vs Pattern B: What the Distinction Means
3. How Cholesterol Particle Size Is Tested
4. Interpreting NMR Lipoprofile Results
5. LDL-P: What Particle Number Tells You That LDL-C Doesn't
6. Discordance: When LDL-C and LDL-P Disagree
7. Who Should Get Cholesterol Particle Size Testing
8. Small Dense LDL Treatment: Lifestyle, Supplements, and Medications
9. HDL Particle Size and Function: The Other Side of the Picture
10. Lp(a): The Particle Statin Therapy Doesn't Touch
11. Monitoring: How to Track Treatment Response Over Time
12. Clinical Decision Framework: Building the Full Lipid Picture
13. Case Study: 52-Year-Old Male With Hidden Pattern B Risk
14. FAQ

---

1. Why Particle Size Matters More Than LDL-C {#1-why-particle-size-matters}

LDL-C has one foundational flaw as a risk marker: it measures cholesterol mass, not particle count. Two patients can have identical LDL-C values — say, 120 mg/dL — and have dramatically different atherogenic burdens depending on whether that cholesterol is carried in a small number of large, buoyant particles or a large number of small, dense ones.

This isn't theoretical. The prospective data is clear and consistent. Framingham Offspring Study data demonstrated LDL-P outperformed LDL-C as a cardiovascular event predictor over a 15-year follow-up.^[1] MESA confirmed the same hierarchy. When the two measures conflict, your patient's risk tracks with particles, not mass.

Why Small, Dense LDL Is More Dangerous

Large, buoyant LDL particles are less atherogenic for two structural reasons:

1. They're too large to easily penetrate the endothelial barrier. Atherogenesis begins in the subendothelial space — and large particles have more difficulty getting there.
2. They clear more rapidly. Large LDL has higher affinity for hepatic LDL receptors and shorter circulation time.

Small, dense LDL (sdLDL, Pattern B) does the opposite. It crosses the endothelium readily, has lower receptor affinity so it stays in circulation longer, and is far more susceptible to oxidative modification — the key step triggering foam cell formation and plaque progression.

The atherogenic cascade for sdLDL: penetrates arterial wall → undergoes oxidation → triggers macrophage uptake → foam cell formation → fibrous cap development → vulnerable plaque → event.

This is the mechanism behind why particle morphology matters. A standard lipid panel is blind to it.

Side-by-side: large buoyant Pattern A (~26 nm) vs small dense Pattern B (~20 nm) penetrating the arterial endothelium.

→ Deep dive: LDL Pattern A vs Pattern B: What It Means for CV Risk — particle morphology, ARIC study data, and the metabolic drivers of Pattern B.

---

2. LDL Pattern A vs Pattern B: What the Distinction Means {#2-ldl-pattern-a-vs-b}

The Pattern A / Pattern B classification was introduced by Ronald Krauss in the 1980s, based on gradient gel electrophoresis studies showing that LDL particles exist in a spectrum of sizes — and that individuals tend toward one dominant phenotype.

Pattern A (Large, Buoyant LDL)

• Particle diameter: >255 Å (approximately 25.5 nm) or >20.6 nm on NMR
• Atherogenicity: Lower — reduced endothelial penetration, faster hepatic clearance
• Associated features: Normal triglycerides, adequate HDL, healthy glucose metabolism
• CV risk implication: Lower relative risk — but Pattern A with high LDL-P is still elevated risk

Pattern B (Small, Dense LDL)

• Particle diameter: <255 Å (<20.6 nm on NMR)
• Atherogenicity: Higher — penetrates the endothelium more readily, oxidizes more easily, circulates longer
• Associated features: The atherogenic lipid triad — elevated triglycerides (>150 mg/dL), low HDL-C, elevated small dense LDL
• CV risk implication: Independent predictor of coronary heart disease, even after adjusting for LDL-C, total cholesterol, and traditional risk factors (ARIC study data)^[3]

In Practice: It's a Spectrum

Most patients don't fall neatly into one category. Modern NMR testing categorizes LDL subfractions (LDL-1 through LDL-7, depending on platform), letting you see whether a patient is predominantly Pattern A, predominantly Pattern B, or in an intermediate mixed zone.

The clinical lesson here: a patient with TG of 190, HDL of 37, and LDL-C of 115 may look borderline-acceptable on a standard panel. NMR on the same patient often reveals LDL-P of 1,600 nmol/L and dominant Pattern B morphology — a completely different risk picture.

→ Full case example and treatment protocols: LDL Pattern A vs Pattern B: What It Means for CV Risk — includes ARIC study sdLDL data and treatment response timelines.

---

3. How Cholesterol Particle Size Is Tested {#3-how-particle-size-is-tested}

Several methods exist for assessing cholesterol particle size and number. Here's what practitioners should know about each.

NMR Lipoprofile (Nuclear Magnetic Resonance Spectroscopy)

The NMR LipoProfile — available through LabCorp/LipoScience — is the most widely used advanced lipid test in functional and preventive medicine. It uses nuclear magnetic resonance spectroscopy to directly measure:

• LDL particle number (LDL-P): Total count of LDL particles (nmol/L)
• LDL particle size: Mean diameter in nanometers; basis for Pattern A vs B classification
• Small LDL-P: Concentration of the most atherogenic small LDL subfractions
• HDL particle number (HDL-P) and HDL particle size: Critical for reverse cholesterol transport assessment
• VLDL particles: Useful in metabolic syndrome evaluation

The NMR's core advantage: it directly counts particles rather than estimating from the Friedewald equation. It's extensively validated in large prospective cohort studies, including the Women's Health Study (n=27,673, 11-year follow-up).^[5] Most FM practitioners lean on this as their primary advanced lipid tool.

Apolipoprotein B (ApoB)

ApoB is the structural protein on every atherogenic lipoprotein particle — LDL, VLDL, IDL, and Lp(a) each carry exactly one ApoB molecule. That means serum ApoB concentration directly equals total atherogenic particle count.

ApoB vs LDL-P: These answer the same fundamental question by different methods. ApoB is available on standard reference lab panels, less expensive, and now recommended by ESC/EAS guidelines (>130 mg/dL = high risk). LDL-P via NMR provides additional particle size subfractionation. In clinical practice: use ApoB when you need particle count affordably; use NMR when you need the full size distribution.^[2]

VAP and Gradient Gel Electrophoresis Platforms

The VAP test (Atherotech/Quest) and gradient gel electrophoresis methods also provide lipoprotein subfractions. Less commonly used in current FM practice, but useful when NMR is inaccessible.

→ Full comparison: NMR Lipoprofile vs Standard Lipid Panel — what NMR measures vs standard panel, LDL-P risk thresholds, when to order, and an annotated sample report walkthrough.

---

4. Interpreting NMR Lipoprofile Results {#4-interpreting-nmr-lipoprofile}

When the NMR Lipoprofile lands on your desk, here's the sequence to work through.

LDL-P risk thresholds: Optimal (<1,000 nmol/L) → Near Optimal (1,000–1,299) → Borderline High (1,300–1,599) → High Risk (≥1,600 nmol/L).

Step 1: LDL Particle Number (LDL-P)

This is the most important single number for most patients.

LDL-P Value	Risk Category
<1,000 nmol/L	Optimal
1,000–1,299 nmol/L	Near optimal / borderline
1,300–1,599 nmol/L	Borderline high
≥1,600 nmol/L	High risk

Some guidelines use >1,200 nmol/L as the threshold for elevated risk. The specific cutoff matters less than the governing principle: when LDL-P conflicts with LDL-C, treatment intensity should track LDL-P.

Step 2: LDL Particle Size

Mean LDL size is reported in nanometers. Pattern A/B classification:

• >20.6 nm = Pattern A dominant (large, buoyant)
• ≤20.6 nm = Pattern B dominant (small, dense)
• 20.3–20.6 nm = Intermediate / mixed pattern

Important: particle size tells you morphology; LDL-P tells you quantity. Assess both. A patient can have Pattern A morphology but still carry very high LDL-P — many large particles still represent elevated particle burden.

Step 3: Small LDL-P

The small LDL-P subfraction is the most atherogenic component of total LDL-P. NMR reports it directly.

Optimal small LDL-P: <527 nmol/L

Elevated small LDL-P + Pattern B morphology + high total LDL-P = the highest-risk lipid constellation identifiable on this test.

Step 4: HDL Particle Count and Size

Low HDL-P (<33.0 μmol/L) is an independent ASCVD risk marker, separate from HDL-C. Small HDL particles have impaired cholesterol efflux capacity — they're less functionally protective than their concentration suggests.

Step 5: VLDL Assessment

Elevated large VLDL particles and large VLDL size are markers of triglyceride-rich lipoprotein burden — the mechanism connecting metabolic syndrome, insulin resistance, and Pattern B LDL. The chain: large VLDL → CETP-mediated cholesterol transfer → depletes HDL → generates small dense LDL. This is the mechanistic story worth explaining to patients.

→ Lab Interpretation Hub — reference ranges, interpretation frameworks, and ordering guidance for the full advanced lipid panel.

---

5. LDL-P: What Particle Number Tells You That LDL-C Doesn't {#5-ldl-particle-number}

LDL-C is a concentration — milligrams of cholesterol per deciliter. LDL-P is a count — the actual number of LDL particles circulating. Why they diverge matters clinically.

2×2 clinical decision matrix: LDL-C (Low/High) × LDL-P (Low/High) — Low Risk / Apparent Risk Only / Hidden Risk — Treat / Confirmed High Risk.

Scenario A: High LDL-C, High LDL-P Both metrics agree. Standard statin candidate. Treat aggressively.

Scenario B: Normal LDL-C, High LDL-P (the "Discordant" Patient) This is the patient who gets missed on a standard panel. LDL-C looks acceptable — but particles are small and cholesterol-poor. Each small dense particle carries less cholesterol per particle, so mass concentration looks fine even as particle count is dangerous. This is the Pattern B patient with "normal" cholesterol who has a cardiovascular event that surprises everyone.

Scenario C: High LDL-C, Normal LDL-P (the "Reverse Discordant" Patient) This patient looks alarming on a standard panel. NMR reveals large, buoyant Pattern A particles — few in number, each carrying abundant cholesterol. Atherogenic burden is lower than LDL-C implies. This patient may not need aggressive therapy that a standard-panel-only clinician would reflexively prescribe.

The governing principle: When LDL-C and LDL-P disagree, event risk tracks with LDL-P. This is why FM practitioners who order NMR regularly treat cases differently than colleagues working from standard panels alone.

→ Clinical decision tree: NMR Lipoprofile vs Standard Lipid Panel — LDL-P risk thresholds, Framingham Offspring Study data, ApoB concordance, and when advanced testing actually changes management.

---

6. Discordance: When LDL-C and LDL-P Disagree {#6-discordance}

Discordance between LDL-C and LDL-P is not rare — it's common in exactly the patient population FM practitioners see most: metabolic syndrome, insulin resistance, type 2 diabetes, hypothyroidism, and post-menopausal women.

Who Gets Discordant Lipid Profiles

Patient Type	Typical Pattern	Why
Metabolic syndrome / insulin resistance	Normal LDL-C, high LDL-P	Insulin resistance → VLDL overproduction → CETP-mediated remodeling → sdLDL
Type 2 diabetes	Normal to low LDL-C, high LDL-P and small LDL-P	Hyperglycemia glycates LDL, impairs clearance, promotes sdLDL
Undertreated hypothyroidism	High LDL-C and high LDL-P	Reduced hepatic LDL receptor expression — both metrics elevated
Post-menopausal women	Variable LDL-C, elevated LDL-P	Loss of estrogen reduces hepatic LDL receptor activity
Lean mass hyperresponders (low-carb/keto)	Very high LDL-C, elevated LDL-P but Pattern A	Fat mobilization-driven large LDL; particle count elevated but buoyant morphology — different risk implications

The lean mass hyperresponder case deserves specific attention. Patients on very low carbohydrate diets often develop high LDL-C with primarily large Pattern A particles and elevated particle number. This is a pattern with different — and actively debated — risk implications versus the classic insulin-resistant Pattern B. NMR is essential for differentiating them. Treating both the same way is a clinical error.

How to Frame Discordance for Patients

The most effective explanation I've found: "Your LDL cholesterol measures how much cargo is in the boxes. NMR tells us how many boxes there are and how big each one is. You have more boxes than your cholesterol number suggests — and they're small, the kind that most easily get into artery walls."

---

7. Who Should Get Cholesterol Particle Size Testing {#7-who-should-get-tested}

Not every patient needs an NMR Lipoprofile. Here's the framework for high-yield ordering.

High Yield: Order NMR or ApoB

• Metabolic syndrome (any 3 of 5 ATP III criteria)
• Type 2 diabetes or pre-diabetes (A1C >5.7%)
• Elevated TG (>150 mg/dL) + low HDL (<40 men, <50 women)
• Intermediate ASCVD risk (5–20% 10-year) where treatment decisions hinge on refined risk stratification
• Family history of premature CVD (men <55, women <65) with an unclear standard lipid picture
• Statin monitoring: Patient at LDL-C goal but with persistent residual risk concerns
• Discordance suspicion: LDL-C looks normal but clinical picture (metabolic markers, body composition, diet history) suggests higher risk

Consider Based on Clinical Picture

• Post-menopausal women starting or on HRT with unclear lipid trajectory
• Patients on very low carbohydrate diets with rising LDL-C where Pattern A vs B distinction changes management
• Autoimmune conditions (lupus, RA) — elevated ASCVD risk independent of standard lipids
• Thyroid disease — undertreated hypothyroidism drives atherogenic lipid changes; NMR quantifies them

Lower Yield

• Young, healthy patients with no metabolic risk factors and low 10-year ASCVD risk
• Established Pattern A on prior testing with stable metabolic status
• Already on aggressive lipotherapy with concordant LDL-C and LDL-P response confirmed on prior NMR

---

8. Small Dense LDL Treatment: Lifestyle, Supplements, and Medications {#8-small-dense-ldl-treatment}

Pattern B is not destiny. Small dense LDL is highly responsive to lifestyle intervention — more so than LDL-C. The metabolic drivers of sdLDL are directly addressable.

Lifestyle Interventions (First-Line, High Impact)

1. Dietary carbohydrate reduction and glycemic management

This is the single most effective lifestyle intervention for Pattern B. The VLDL overproduction → CETP-mediated sdLDL cascade is driven by hepatic de novo lipogenesis from excess carbohydrates — particularly fructose and high-glycemic starches. Reducing them directly reduces VLDL production, lowers triglycerides, and shifts LDL morphology toward Pattern A.

Clinical target: fasting TG <100 mg/dL. When TG drops below 130 mg/dL, LDL particle size almost invariably shifts toward Pattern A.

2. Weight loss (even modest)

A 5–10% weight reduction in overweight patients consistently reduces small LDL-P, total LDL-P, and triglycerides while increasing HDL-P and particle size. Adipose dysfunction in visceral obesity contributes to elevated FFAs → hepatic VLDL synthesis → Pattern B. The root cause is the adiposity.^[4]

Insulin Resistance → Hepatic VLDL overproduction → CETP-mediated cholesterol transfer → Small Dense LDL (Pattern B) + Depleted HDL.

3. Aerobic exercise

Moderate-intensity aerobic exercise (150+ min/week) reduces TG, increases HDL-C, and improves LDL particle size. The mechanism: increased lipoprotein lipase activity improves VLDL clearance, reducing the substrate for sdLDL formation.

4. Sleep and stress optimization

Chronically elevated cortisol drives hepatic VLDL overproduction — the same upstream mechanism as dietary carbohydrates. Patients with adrenal dysregulation often have worse lipid particle profiles than their diet alone would predict. Addressing sleep quality and HPA dysregulation isn't soft medicine. It's directly atherogenesis-relevant biology.

Supplements With Evidence for Pattern B

Supplement	Mechanism	Dosing	Evidence
Omega-3 fatty acids (EPA + DHA)	Reduces hepatic VLDL synthesis, lowers TG, shifts LDL toward Pattern A	2–4 g/day EPA+DHA	Strong (multiple RCTs, REDUCE-IT)[6]
Niacin (nicotinic acid)	Reduces VLDL synthesis, raises HDL, improves LDL particle size	500–2,000 mg/day extended release	Moderate (mechanism strong; outcome trials mixed)
Soluble fiber (psyllium, beta-glucan)	Reduces hepatic cholesterol synthesis via bile acid sequestration; improves insulin sensitivity	10–30 g/day	Moderate
Berberine	Activates AMPK → reduces hepatic lipogenesis, improves insulin sensitivity	500 mg TID	Moderate (strong in T2D population, lipid benefit well-documented)
Magnesium	Improves insulin sensitivity; deficiency associated with Pattern B	200–400 mg/day glycinate form	Indirect / supportive

Medications

Fibrates (fenofibrate, gemfibrozil) Fibrates are the drug class most specifically targeting Pattern B. They activate PPARα → reduce VLDL synthesis, raise HDL, and dramatically lower triglycerides. Fenofibrate 145 mg/day typically produces 30–50% triglyceride reduction, HDL increase of 5–15%, and a meaningful LDL particle size shift toward Pattern A.

High-intensity statins Statins lower LDL-C and LDL-P through LDL receptor upregulation. They reduce overall atherogenic burden but don't specifically target particle morphology with the same precision as fibrates. For Pattern B patients with both elevated LDL-P and small dense LDL, statin + fenofibrate combination is often the most comprehensive pharmacologic approach.

Icosapentaenoic acid (Vascepa) High-dose prescription EPA (4 g/day) from REDUCE-IT demonstrated 25% MACE reduction in high-TG statin-treated patients. It lowers TG, reduces VLDL, and improves LDL particle size. For high-risk Pattern B patients already on statin therapy, this is proven incremental therapy.^[6]

PCSK9 inhibitors These dramatically lower LDL-P and LDL-C in patients with inadequate statin response. Less specifically indicated for Pattern B vs Pattern A distinction — they reduce total particle burden across the board.

→ Full treatment protocol: LDL Pattern A vs Pattern B: What It Means for CV Risk — treatment decision framework, supplement evidence hierarchy, medication timing, and response monitoring.

---

9. HDL Particle Size and Function: The Other Side of the Picture {#9-hdl-particle-size}

HDL has a particle size story that mirrors LDL — and it's clinically underappreciated.

HDL-C vs HDL-P: The Same Discordance Problem

Just as LDL-C can underestimate risk, HDL-C can overestimate protection. A patient with HDL-C of 50 mg/dL may have low HDL particle number (HDL-P) — large, cholesterol-rich particles, but few of them. The reverse cholesterol transport function of HDL depends on particle count (more particles = more capacity for cholesterol efflux from macrophages in arterial plaques), not just cholesterol concentration.

HDL-P <33.0 μmol/L: Associated with increased ASCVD risk, independent of HDL-C.

HDL Particle Size and Functionality

Large HDL particles are more functional — better at cholesterol efflux from foam cells in atherosclerotic lesions. Small, dysfunctional HDL particles have impaired efflux capacity. Conditions that most consistently impair HDL functionality include metabolic syndrome, chronic inflammation, oxidative stress, and kidney disease.

What to do about low HDL-P:

• Aerobic exercise is the most effective intervention for raising HDL-P
• Niacin raises both HDL-C and HDL-P
• Omega-3s produce modest HDL-P benefits
• Addressing metabolic syndrome root causes is the definitive intervention — HDL particle count tends to improve as insulin sensitivity improves

---

10. Lp(a): The Particle Statin Therapy Doesn't Touch {#10-lpa}

Lipoprotein(a) — Lp(a) — is an LDL-like particle with an additional apolipoprotein(a) attached. It deserves its own section:

1. Largely genetically determined — 80%+ of Lp(a) levels are inherited, not lifestyle-driven
2. Statins don't lower it — and may marginally raise it in some patients
3. Independent, powerful cardiovascular risk factor — especially for premature MI, aortic stenosis, and stroke

Lp(a) Risk Thresholds

Lp(a) Level	Risk Classification
<30 mg/dL (<75 nmol/L)	Low risk
30–50 mg/dL (75–125 nmol/L)	Intermediate risk
>50 mg/dL (>125 nmol/L)	High risk — independent risk enhancer per ACC/AHA 2018 guidelines

Important: Lp(a) assays report in either mg/dL or nmol/L — these are not interchangeable. nmol/L is the more accurate measurement. Always check units when interpreting.

Treatment Approach for Elevated Lp(a)

Honest answer: current options are limited. Lifestyle changes don't significantly move Lp(a). Niacin at high doses (1,500–2,000 mg/day) can reduce Lp(a) by 15–25% — the best currently available non-pharmacologic option. PCSK9 inhibitors reduce Lp(a) by 20–30%. Dedicated Lp(a)-lowering therapies (muvalaplin, olpasiran, pelacarsen) are in late-stage trials and likely available within 2–3 years.

For now: elevated Lp(a) should heighten urgency around aggressively treating every other modifiable risk factor.

Clinical rule: Every FM patient with unexplained premature CVD, family history of MI before age 60, or aortic stenosis should have Lp(a) tested once. It doesn't go on a standard panel and gets missed for years.

---

11. Monitoring: How to Track Treatment Response Over Time {#11-monitoring-response}

Retesting Schedule

Phase	Timing	What to Order
Baseline	At diagnosis / risk discovery	Full NMR Lipoprofile + ApoB + Lp(a) + standard panel
Initial response	8–12 weeks after intervention	NMR Lipoprofile + standard panel
Stable monitoring	Every 6 months (year 1), then annually	NMR or ApoB + standard panel; more frequent if titrating

What Counts as Treatment Response

For Pattern B:

• TG <130 mg/dL: Strong predictor that LDL morphology has shifted toward Pattern A
• LDL-P <1,000 nmol/L: Optimal target
• Small LDL-P <527 nmol/L: Meaningful reduction in most atherogenic subfraction
• LDL particle size increase toward >20.6 nm: Confirmation of Pattern A shift

Common Monitoring Pitfalls

"My LDL-C went up on a low-carb diet" — One of the most common scenarios creating unnecessary alarm. When patients reduce carbohydrates, TG typically drops and HDL rises. LDL-C may simultaneously rise due to increased large buoyant particles. If NMR shows LDL-P stable or falling with particle size increasing, the lipid profile is actually improving. Don't treat the LDL-C number in isolation.

Statin response that looks good on LDL-C but doesn't resolve LDL-P — Some patients respond to statins with large LDL-C reductions but modest LDL-P reductions. If cardiovascular risk is driving treatment decisions, LDL-P should be the target — and these patients often need adjunctive therapy (fibrate, ezetimibe, high-dose omega-3) to fully address particle burden.

---

12. Clinical Decision Framework: Building the Full Lipid Picture {#12-clinical-framework}

Advanced lipid testing is most powerful when interpreted as a system. Here's the synthesis framework.

Step 1: Establish the Metabolic Context

Before interpreting any single lipid number, establish:

• Is this patient insulin resistant? (fasting glucose, A1C, HOMA-IR, waist circumference, TG:HDL ratio)
• Is there significant central obesity?
• Are triglycerides elevated (>150 mg/dL)?
• What is HDL-C? (Low = metabolic syndrome component)

Why it matters: Metabolic syndrome is the driver of Pattern B LDL. Without addressing root cause, treating the downstream lipid numbers is playing whack-a-mole with cardiovascular risk.

Step 2: Assess Particle Number (LDL-P or ApoB)

LDL-P drives event risk. If elevated — regardless of what LDL-C says — treatment intensity calibrates to LDL-P.

Practical targets: LDL-P <1,000 nmol/L (ApoB <80 mg/dL) for high-risk patients; <1,200 nmol/L for intermediate risk.

Step 3: Assess Particle Morphology

NMR particle size and small LDL-P tell you which particles are driving the elevated LDL-P. Pattern B + elevated small LDL-P = highest atherogenic burden. This guides treatment prioritization: fibrates + lifestyle for the Pattern B driver, statins for overall particle reduction.

Step 4: Assess HDL Particle Count and Quality

Low HDL-P means reduced reverse cholesterol transport capacity — the protective mechanism that pulls cholesterol out of arterial plaques. It doesn't improve unless metabolic root causes are addressed.

Step 5: Check Lp(a) Once

Genetically determined, doesn't change with lifestyle, measure once unless tracking response to niacin or PCSK9 inhibitors. Elevated Lp(a) shifts the overall risk picture and heightens urgency on every other modifiable factor.

Step 6: Build the Root Cause Narrative

Synthesize everything into a coherent clinical picture. Here's the kind of note that captures it:

"This patient has Pattern B LDL (particle size 19.8 nm, small LDL-P 890 nmol/L, total LDL-P 1,550 nmol/L) in the setting of metabolic syndrome (TG 210 mg/dL, HDL 36 mg/dL, waist 43", fasting glucose 108 mg/dL). The atherogenic lipid triad is present. Standard panel shows LDL-C 112 mg/dL — falsely reassuring. Lp(a) 38 mg/dL (intermediate risk). Root cause: insulin resistance driving hepatic VLDL overproduction → CETP-mediated small dense LDL formation → impaired HDL maturation. Treatment must address insulin resistance first; lipid medications address the downstream consequence."

This kind of synthesis — from particle morphology back to metabolic root cause — is what a functional medicine lipid assessment provides that a standard panel never will.

---

13. Case Study: 52-Year-Old Male — "Normal Cholesterol" With Hidden Pattern B Risk {#13-case-study}

Presentation: Annual physical. No symptoms. A1C 5.9% (flagged as pre-diabetic). BMI 31. Waist 43". Blood pressure 136/86 mmHg.

Standard lipid panel (before):

• Total cholesterol: 195 mg/dL
• LDL-C: 118 mg/dL
• HDL-C: 38 mg/dL
• Triglycerides: 180 mg/dL

At standard panel level: Triglycerides slightly elevated, HDL low. LDL-C within range. Most clinicians counsel lifestyle changes and recheck in a year.

NMR Lipoprofile (before):

• LDL-P: 1,450 nmol/L (HIGH — optimal <1,000)
• LDL particle size: 19.8 nm (Pattern B dominant)
• Small LDL-P: 940 nmol/L (HIGH — optimal <527)
• HDL-P: 27.1 μmol/L (LOW — optimal >33)
• Large VLDL-P: Elevated

ApoB: 118 mg/dL (HIGH — optimal <80 mg/dL)

Lp(a): 38 mg/dL (intermediate risk)

The full picture: Classic insulin-resistant atherogenic lipid triad. His LDL-C of 118 mg/dL dramatically underestimates atherogenic burden — he has approximately 30% more LDL particles than a Pattern A patient at the same LDL-C, with particles far more prone to endothelial penetration and oxidative modification. Combined with intermediate Lp(a) and metabolic syndrome, actual cardiovascular risk is substantially higher than a 10-year ASCVD calculator using LDL-C alone would show.

Treatment plan:

1. Low-glycemic Mediterranean diet — eliminate refined carbohydrates and fructose-sweetened beverages
2. Walking 30 min/day; build to 150+ min/week brisk walking over 6 weeks
3. Omega-3s (EPA + DHA) 3 g/day
4. Metformin 500 mg BID (pre-diabetes + cardiometabolic benefit)
5. Berberine 500 mg TID (AMPK activation, insulin sensitization)
6. Repeat NMR Lipoprofile at 12 weeks

Before/after: Triglycerides (180→120 mg/dL), HDL-C (38→44 mg/dL), LDL-P (1,450→1,050 nmol/L), Small LDL-P (940→510 nmol/L).

Outcome at 12 weeks:

Marker	Before	After	Change
Triglycerides	180 mg/dL	120 mg/dL	−33%
HDL-C	38 mg/dL	44 mg/dL	+16%
LDL-P	1,450 nmol/L	1,050 nmol/L	−28%
LDL particle size	19.8 nm (Pattern B)	20.4 nm (near Pattern A)	+0.6 nm
Small LDL-P	940 nmol/L	510 nmol/L	−46%
A1C	5.9%	5.7%	−0.2%

No statin was initiated. Lifestyle plus targeted supplementation moved this patient from high-risk Pattern B to near-optimal particle profile in 12 weeks. Continued monitoring planned at 6 months with consideration of low-dose fenofibrate if TG and particle size haven't fully normalized.

---

14. FAQ {#14-faq}

Q: What is a normal cholesterol particle size?

A favorable LDL particle size is generally considered >20.6 nm, corresponding to the Pattern A phenotype (large, buoyant particles). Particle size <20.6 nm indicates Pattern B (small, dense LDL), which carries higher atherogenic risk due to easier endothelial penetration and longer circulation time. That said, particle size must always be interpreted alongside particle number (LDL-P) — a patient with large particles but very high LDL-P still has meaningful atherogenic burden. The most favorable profile is Pattern A morphology and LDL-P below 1,000 nmol/L.

---

Q: Can you have Pattern B LDL with normal cholesterol levels?

Yes — and this is exactly why cholesterol particle size testing matters clinically. LDL-C measures cholesterol mass, not particle count or morphology. A patient with TG of 200 mg/dL, HDL of 36 mg/dL, and LDL-C of 110 mg/dL appears borderline-acceptable on a standard panel. NMR on the same patient often reveals small dense Pattern B particles with LDL-P well above 1,400 nmol/L — a significantly elevated cardiovascular risk profile that the standard panel completely missed. The atherogenic lipid triad (elevated TG, low HDL, Pattern B) can coexist with apparently normal LDL-C in metabolically complex patients.

---

Q: Is the NMR Lipoprofile covered by insurance?

Coverage varies by insurer, plan, and clinical indication. Many insurance plans cover NMR Lipoprofile (CPT code 83704) when ordered with appropriate diagnostic justification — particularly for patients with metabolic syndrome, diabetes, or intermediate ASCVD risk. Some plans require prior authorization. Cash pay pricing typically runs $80–$150 depending on the lab. ApoB (CPT 82172) is generally less expensive and more consistently covered as an alternative for quantifying atherogenic particle burden when the full size distribution isn't required.

---

Q: How does Pattern B LDL develop?

Pattern B develops primarily through a metabolic chain driven by insulin resistance and excess triglyceride production: (1) insulin resistance → hepatic de novo lipogenesis → excess VLDL secretion; (2) elevated VLDL → CETP activity → transfers cholesterol from HDL to VLDL/LDL; (3) hepatic lipase acts on cholesterol-enriched LDL → generates small, dense LDL particles; (4) simultaneously, HDL is depleted of cholesterol → small, dysfunctional HDL particles result. The end product is the atherogenic lipid triad. This mechanistic chain explains why addressing insulin resistance — through dietary carbohydrate reduction, weight loss, and aerobic exercise — is the most effective way to reverse Pattern B morphology.

---

Q: Does a statin fix Pattern B LDL?

Partially. Statins reduce LDL-P (total particle number) by upregulating hepatic LDL receptors — beneficial regardless of pattern. However, statins don't specifically target the metabolic processes driving Pattern B morphology. They don't substantially reduce VLDL overproduction, and they have modest effects on triglycerides and particle size. For Pattern B patients, fibrates (which directly reduce VLDL synthesis and improve LDL particle size) and lifestyle intervention addressing insulin resistance are the most targeted approaches. High-risk Pattern B patients often benefit from statin + fibrate combination therapy alongside aggressive lifestyle change.

---

Q: What's the difference between LDL-P and ApoB?

Both measure atherogenic particle burden, just by different methods. ApoB measures the total count of all atherogenic lipoprotein particles (LDL + VLDL + IDL + Lp(a)) — since each particle carries exactly one ApoB molecule, serum ApoB concentration equals total atherogenic particle count. LDL-P via NMR measures LDL-specific particle count and also provides particle size distribution. In most patients, LDL-P and ApoB are concordant and provide equivalent risk information.^[2] ApoB is available on standard reference lab panels and is less expensive; NMR adds particle size subfractionation. Both are superior to LDL-C alone for cardiovascular risk assessment.

---

Q: How long does it take to reverse Pattern B with lifestyle changes?

In clinical practice and research studies, meaningful improvement in LDL particle morphology typically occurs within 8–12 weeks of consistent dietary carbohydrate reduction, weight loss, and regular aerobic exercise. The most sensitive early marker is the triglyceride response: when TG drops below 130 mg/dL, particle size almost always shifts toward Pattern A. Full normalization of LDL-P often takes 3–6 months. Repeating NMR at 12 weeks gives a realistic assessment of lifestyle response — and helps determine whether pharmacologic adjuncts are needed. Don't make that call at 4 weeks.

---

Citations {#citations}

1. PMID 19657464 — Cromwell WC, Otvos JD, Keyes MJ, et al. LDL Particle Number and Risk of Future Cardiovascular Disease in the Framingham Offspring Study — Implications for LDL Management. J Clin Lipidol. 2007;1(6):583–592. https://pubmed.ncbi.nlm.nih.gov/19657464/ | PMC: https://pmc.ncbi.nlm.nih.gov/articles/PMC2720529/

2. PMID 23386699 — Contois JH, McConnell JP, Sethi AA, et al. Apolipoprotein B and Cardiovascular Disease Risk: Position Statement from the AACC Lipoproteins and Vascular Diseases Division. Clin Chem. 2009;55(3):407–419. https://pubmed.ncbi.nlm.nih.gov/23386699/

3. PMC3999643 — Hoogeveen RC, Gaubatz JW, Sun W, et al. Small Dense Low-Density Lipoprotein-Cholesterol Concentrations Predict Risk for Coronary Heart Disease: The Atherosclerosis Risk in Communities (ARIC) Study. Arterioscler Thromb Vasc Biol. 2014;34(5):1069–1077. https://pmc.ncbi.nlm.nih.gov/articles/PMC3999643/

4. PMC2837149 — Krauss RM, Blanche PJ, Rawlings RS, Fernstrom HS, Williams PT. Reversal of Small, Dense LDL Subclass Phenotype by Normalization of Adiposity. Obesity (Silver Spring). 2009;17(9):1768–1775. https://pmc.ncbi.nlm.nih.gov/articles/PMC2837149/

5. PMID 19204302 — Mora S, Otvos JD, Rifai N, Rosenson RS, Buring JE, Ridker PM. Lipoprotein Particle Profiles by Nuclear Magnetic Resonance Compared with Standard Lipids and Apolipoproteins in Predicting Incident Cardiovascular Disease in Women. Circulation. 2009;119(7):931–939. https://pubmed.ncbi.nlm.nih.gov/19204302/

6. PMID 30415628 — Bhatt DL, Steg PG, Miller M, et al. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia (REDUCE-IT). N Engl J Med. 2019;380(1):11–22. https://pubmed.ncbi.nlm.nih.gov/30415628/

7. LabCorp NMR LipoProfile (CPT 83704): https://www.labcorp.com/tests/092560/nmr-lipoprofile

8. ACC/AHA 2018 Guideline on the Management of Blood Cholesterol: https://www.acc.org/latest-in-cardiology/ten-points-to-remember/2018/11/09/14/28/2018-guidelines-on-the-management-of-blood-cholesterol

---

Call to Action

Advanced lipid testing is only as useful as the clinical decision-making behind it.

Your metabolically complex patients — the pre-diabetic with "normal" LDL-C, the post-menopausal woman whose standard panel looks fine, the lean-mass hyperresponder on keto with a skyrocketing LDL-C — all have one thing in common: a standard lipid panel isn't enough to guide their care.

HANS reads your NMR Lipoprofile, ApoB, and Lp(a) results alongside the full clinical picture — metabolic markers, medication history, diet, and risk factors — and helps you document a defensible, nuanced treatment plan without spending an extra hour per chart.

→ See how HANS works for FM practitioners

---